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Abstract 
 Nanoparticle (NP) delivery of chemotherapeutic drugs can be used to both improve tumor 
toxicity and reduce toxicity to normal tissue in chemo and chemoradiotherapy (CRT). However, 
various properties of nanoparticles with respect to CRT are yet to be explored. For instance, it is 
unknown how particle size may affect the therapeutic index of CRT. Exploration of this topic may 
provide invaluable insight on how NP-based CRT could be administered clinically in the future, 
as there is currently no set standard on an optimal particle size. PEG-PLGA nanoparticles were 
engineered encapsulating either the DNA-PK inhibitor Wortmannin (wtmn) or the ATM inhibitor 
KU60019 of various sizes (50, 100, or 150 nm in diameter) and studied their biodistribution, 
efficacy, and toxicity in CRT. Effects in vitro were observed in three colorectal adenocarcinoma 
lines (HT-29, SW480, and LoVo) and in vivo in mice. These nanoformulations were shown to be 
both cytotoxic and radiosensitizing in these cell lines, and there was no effect of particle size on 
toxicity in vitro. The largest particles were most rapidly cleared by the liver, but still penetrated 
tumors well in vivo. All sizes of nanoformulations were effective radiosensitizers of rectal tumor 
xenografts in vivo. In no instance did the largest or smallest particles appear to demonstrate any 
greater efficacy than medium sized particles when combined with radiation. The 50 nm KU60019 
particles caused greater bowel toxicity than larger particles, and the 100 nm Wortmannin particles 
induced significantly more radiosensitization than larger or smaller particles in SW480 xenografts, 
a trend that was also observed in most other tumor/drug combinations. Radiation-induced rectal 
toxicity was minimal in animals treated with all three particle sizes. There was also no significant 
effect of particle size on hematologic of hepatotoxicity. These results demonstrate that particles in 
the 100 nm size range may be optimal for clinical applications in chemoradiotherapy.  
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Introduction 
Background 
 Historically, several drugs with the potential to be used as powerful chemotherapeutics 
were abandoned in clinical development due to high toxicity to normal tissue or poor stability or 
solubility in blood. For instance, Wortmannin, despite being a potent anti-cancer agent, was 
deemed too hepatotoxic for patient use and demonstrated poor solubility and stability in preclinical 
studies. Because traditional chemotherapies are system-wide, they are not targeted towards a 
primary tumor; thus, toxicity to normal tissue is strictly monitored.1 This problem remains an issue 
for drugs approved for chemotherapy, as patients may have adverse reactions to the drugs and must 
stop treatment before they can effectively treat their cancer. As such, the search to find a targeted 
way to treat cancers while minimizing damage to normal tissue is crucial. 
Targeted chemotherapy in the form of polymeric nanoparticle drug delivery is a method 
currently being studied for its ability to increase effectiveness against cancerous tumors while 
minimizing normal tissue toxicity. Several types of cancers, including many rectal cancers, have 
defective vasculature serving the primary tumor. This leaky vasculature combined with poor 
lymphatic draining systems, allows for less selective permeability and greater retention of 
materials into the tumor.2 Nanoparticles are then able to better penetrate cancerous tumor 
vasculature than that of normal tissue. Nanoparticle formulation of drugs like Wortmannin showed 
decreased toxicity, increased stability and solubility, and increased effectiveness as an anti-cancer 
agent in preclinical studies.1 
Chemoradiotherapy 
 CRT is used to treat various types of solid cancers, including those of the rectum, lungs, 
esophagus, and head and neck.3 Radiosensitizers, which improve the efficacy of radiotherapy, are 
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often given concurrently with radiation.4 While this improves efficacy, it often comes at the price 
of excess toxicity as normal tissues are also sensitized to radiation. Several pre-clinical studies 
have demonstrated that nanoformulations of radiosensitizers can improve the therapeutic index of 
chemoradiotherapy by improving tumor-specific delivery of the drug and reducing normal tissue 
exposure.1 These studies suggest that the rational development and translation of radiosensitizing 
nanoformulations can improve clinical outcomes for cancer patients.  
 One critical limitation to the development and translation of nanotherapeutics for use as 
radiosensitizers is that very little is currently known about the optimal particle characteristics for 
this indication. Physical characteristics, such as particle size, can drastically affect biodistribution 
and other important pharmacokinetic properties. It is generally believed that nanoparticles in the 
sub-50 nm range are desirable as drug delivery vehicles since they should rapidly penetrate tumors 
and be cleared less quickly than larger particles.5 However, it is unclear if these properties are 
desirable in chemoradiotherapy applications in which the goal is to maximize differences between 
normal tissue and tumor drug concentrations. Since radiation is the predominant source of local 
tumor damage in chemoradiotherapy, it is possible that larger particles (100 – 150 nm) may be 
equally if not more efficacious with less toxicity to normal tissue than smaller particles. By 
examining the relationship between particle size and therapeutic index, a rational design for 
nanoparticle drug formulations may be optimized for use in chemoradiotherapy. 
 In this study, the efficacy and toxicity of polymeric (mPEG-PLGA) nanoformulations of 
the DNA repair inhibitors Wortmannin and KU60019 of three different sizes (50, 100, and 150 
nm) were compared in mouse models of colorectal cancer. Wortmannin is a potent inhibitor of 
DNA-PK and PI3 kinase.6 KU60019 specifically inhibits ATM, a protein kinase recruited and 
activated by double-stranded breaks in DNA.7 The efficacy, toxicity, and biodistribution of these 
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three distinct nanoformulations were compared when combined with radiation in mouse xenograft 
models of colorectal cancer.  
Materials and Methods 
Materials 
KU60019 and Wortmannin were purchased from Apex Bio (Houston, Texas). Methoxy-
poly(ethylene glycol)-block-poly(lactic-co-glycolic acid) (mPEG-PLGA) with molecular weights 
of 2000:15,000 Da (PEG(2K):PLGA(15K)) and 5000:10,000 Da (PEG(5K):PLGA(10K)) were 
purchased from PolySciTech (West Lafayette, IN). Poly(D,L-lactic acid) (PLA) with an average 
molecular weight of 18,000 – 28,000 was purchased from Sigma-Aldrich (St. Louis, MO). 
Acetonitrile (HPLC grade) and double distilled water (HPLC grade) were purchased from Sigma-
Aldrich (St. Louis, MO). Flamma Fluor (FKR648) was purchased from Akina, Inc. (West 
Lafayette, IN).  
Nanoparticle Preparation  
 Nanoprecipitation was used to create nanoparticles of each of the different sizes. Polymers 
and drugs were dissolved in ACN (mPEG_PLGA at 40 mg/mL; PLA, KU60019, Wortmannin at 
2 mg/mL). Drug-polymer mixtures brought to a final volume of 1 mL in ACN were added 
dropwise to 3 mL double deionized water over rapid stirring (800 – 1200 rpm) at room 
temperature. The mixture was constantly stirred under vacuum at room temperature for 3 hours to 
allow self-assembly and evaporation of the organic solvent (ACN). Nanoparticles were then 
centrifuged for 15 min at 8000 x G in 30 KDa cut-off centrifuge filters (Millipore, Billerica, MA), 
washed in 1 mL 1x Dulbecco’s phosphate-buffered saline (DPBS) followed by repeat 
centrifugation. After three washes, the particles were resuspended to desired concentrations in 1x 
DPBS or tissue culture media.  
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 Nanoparticle size was adjusted by modifying polymer compositions within the ACN. 50 
nm particles were obtained by adding 5 mg of 5000:10,000 mPEG-PLGA and 500 µg (10%) drug. 
100 nm particles were generated by adding 5 mg 2000:15,000 mPEG-PLGA, 3 mg PLA, and 800 
µg (10%) drug. 150 nm particles were created by adding 7 mg 2000:15,000 mPEG-PLGA, 9 mg 
PLA, and 800 µg (5%) drug. Drug-free particles of each size were created by bringing polymeric 
solutions to volume.  
Nanoparticle Characterization 
 Purified nanoparticles encapsulating Wortmannin or KU60019 were characterized by 
transmission electron microscopy (TEM), dynamic light scattering, and aqueous electrophoresis. 
Prior to TEM imaging, concentrated NP samples were diluted to 5 mg/mL in deionized water. A 
5 µL sample of each was mixed with 5 µL 4% uranyl acetate aqueous solution before being added 
to a 400 mesh carbon-filmed copper grid. TEM images were captured using a Zeiss TEM 910 
transmission electron microscope operated at 80 kV (Carl Zeiss Micrscopy, LLC, Thornwood, 
NY) in the Microscopy Services Laboratory core facility at the UNC School of Medicine. 
Intensity-average diameter and mean zeta potential (ζ) of nanodispersions were determined by 
dynamic light scattering and an aqueous electrophoresis method using a Zetasizer Nano ZS 
instrument (Malvern Inc, Worcestershire, UK). All measurements were based on the average of 
three separate measurements.  
Drug Loading Efficiency 
 Loading efficiency of KU60019 or Wtmn in the nanoparticles was measured with a 
Shimadzu SPD-M20A high pressure liquid chromatography (HPLC) system (Shimadzu, Kyoto, 
Japan) equipped with a diode array detector at a GP-C18 reverse phase column (pore size = 120 
A, 4.6 x 150 nm, Sepax Technology, Newark DE). For preparation, 100 µL of purified particles 
11 
 
was dissolved in 100 µL of ACN, vortexed vigorously, and stored over night at 4°C to allow 
complete dissolution of particles. Drug concentrations were determined by generating standard 
curves from 0 – 100 µM for each drug. A linear gradient from 10% ACN in water to 100% ACN 
was run over 15 min, followed by 100% ACN for 5 min, then 10% ACN for 5 min. Flow rate used 
was 1 mL/min. Wtmn eluted with a retention time of 5.6 min and was detected at a wavelength of 
250 nm. KU60019 eluted with a retention time of 6.4 min and was detected at a wavelength of 230 
nm. Drug loading (wt/wt%) was calculated as (wt drug mg/wt polymer mg) x 100%. Encapsulation 
efficiency was calculated as (concentration of drug in dissolved particles/concentration of drug in 
initial organic phase solution) x 100%. 
Drug Release Studies 
 Release rates of the drugs were measured using 100 µL of purified nanoparticles diluted to 
2.5 mg/mL into Slide-A-Lyzer MINI dialysis tubes with a molecular weight cut-off of 10 kDa 
(Pierce, Rockford, IL) and dialized against 4 L of 1x DPBS with gentle stirring (50 rpm) at 37°C. 
At selected times (0, 1, 3, 6, 12, and 24 hours for Wtmn, 0, 1, 2, 3, 6, 12, 24, 48, and 72 hours for 
KU60019), the entire sample in a dialysis tube was removed and dissolved in equal parts ACN to 
allow dissolution overnight. Drug concentrations were determined using HPLC, as described 
above. Drug loading and encapsulation efficiency were determined at time 0 (immediately after 
initial purification). Drug release half-time (T1/2) is defined as the time for half the encapsulated 
drug to be released and was calculated using GraphPad Prism software V4.0 (La Jolla, CA).  
In Vitro Studies 
Cell Culture: Human colorectal adenocarcinoma cell lines HT-29, SW480, and LoVo were 
collected from the University of North Carolina tissue culture facility in the Lineberger 
Comprehensive Cancer Center. Cells were cultured using Dulbecco’s Modified Eagle Medium 
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(DMEM): Nutrient Mixture F-12 (Gibco, Thermo Fisher Scientific, Waitham, MA) supplemented 
with 10% (v/v) Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin.  
 MTS Cell Viability Assays: In vitro toxicities of the different sized nanoparticles of 
KU60019 and Wtmn were determined using MTS cell viability assays. Cells were plated in 96 
well plates at densities of 10,000 cells per well, left to adhere overnight, then treated with varying 
concentrations of drugs. For cells treated with Wtmn, drug was removed after 3 hours, and cells 
were washed twice with sterile DPBS and grown in fresh media for 48 hours at 37°C. For cells 
treated with KU60019, drug was removed after 24 hours, and cells were washed twice with sterile 
DPBS, and grown in fresh media for another 24 hours at 37°C. Cell viability was assessed using 
MTS reagent (Promega, Madison WI). Absorbance was recorded at 492 nm using a 96-well plate 
reading (Infinite 200 Pro, Tecan i-control). Relative cell survival was determined by dividing the 
intensity of each well by the average intensity obtained in wells containing cells treated without 
drug multiplied by 100. All conditions were done in triplicate. 
 Clonogenic Cell Survival Assays: In vitro radiosensitization effects of KU60019 and Wtmn 
were determined using clonogenic cell survival assays. Cells were cultured at densities ranging 
from 100 – 40,000 cells per dish for 24 hours. Media was then replaced with media containing 
varying concentrations of NP-encapsulated drugs. Cells treated with KU60019 (2.5 µM for HT-
29 and SW480, 1.5 µM for LoVo) were radiated with 0, 2, 4, 6, or 8 Gy of radiation after 3 hours, 
then left with media unchanged for an additional 21 hours for a total of 24 hours. Media was then 
removed, and cells were washed twice with sterile DPBS and cultured in fresh media at 37°C for 
12 days. For Wtmn experiments, cells were treated with media containing free or NP Wtmn 
(equivalent to 20 µM for HT-29 and SW480, 15 µM for LoVo) for 3 hours followed by the same 
doses of radiation. Cells were then washed twice with sterile PBS and cultured in fresh media at 
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37°C for 12 days. Cells were then fixed in a 4% (v/v) neutral buffered formalin solution and stained 
with trypan blue. All colonies with at least a single cell were counted. All conditions were done in 
triplicate.  
In Vivo Studies 
 Mice were maintained in the Center for Experimental Animal Studies (an AAA LAC-
accredited experimental animal facility) at the University of North Carolina. All procedures 
involving mice were done in accordance with protocols approved by the University of North 
Carolina Institutional Animal Care and Use Committee (IACUC) and conformed to the Guide for 
the Care and Use of Laboratory Animals (NIH publication no. 86 – 23). Athymic nude mice were 
obtained from UNC animal services core (Chapel Hill, NC). C57bl/6J mice were obtained from 
Jackson Labs (Barr Harbor, ME).  
Antitumor Efficacy: Xenograft tumors were injected into the left flanks of male nude 
athymic mice (6 – 7 weeks old, 28 – 30 g). For HT-29, mice were inoculated with 1 x 106 cells in 
a 1:1 mixture of plain DMEM F-12 media:matrigel mixture. The average tumor volume after 7 
days was 200.0 mm3. For SW 480, mice were inoculated with 2.25 x 106 cells in a 1:1 mixture of 
plain DMEM F-12 media:matrigel mixture. Average tumor volume after 10 days was 166.3 mm3. 
For these experiments, a fractionated radiation schedule with repeated dosing of NPs was utilized. 
This type of treatment schedule is clinically relevant as radiation is most frequently given in a 
fractionated manner. Further, radiation is known to affect vascular permeability and structure8 
which could in turn affect anti-tumor efficacy or toxicity of particles in a size-dependent manner.  
On the first day of treatment (7 days after inoculation for HT-29, 10 days after inoculation 
for SW480), animals were injected with saline or NP drug (50, 100, 150 nm formulations) via tail 
vein injection (0.07 mg/kg Wtmn and 0.5 mg/kg KU60019). Three hours after injection, tumors 
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were irradiated at 5 Gy using a Precision X-Ray: X-RAD 320 irradiation system (Precision X-Ray 
Inc) operating at 320 KVp and 12.5 mA. The source-surface distance was 47 cm at a dose rate of 
100 cGy/min. For radiation, the tumors were left exposed and mice were shielded with 4 mm of 
lead. On the second day, animals were again treated with 5 Gy of radiation with no drug. On day 
3, animals were again injected with saline or NP drug and treated with 5 Gy radiation 3 hours later. 
To test the effects of particle size on chemotoxicity without radiation, a separate control group  of 
mice were treated with saline or NP formulations on days 1 and 3 with no radiation. Tumor volume 
was measured every 3 days via manual caliper measurements in two perpendicular directions. 
Tumor volume was calculated as 0.5 * x * y2, where x is the larger dimension and y is the smaller 
dimension. Mice were euthanized by CO2 overdose when tumors exceeded 20 mm in greatest 
dimension or reached 3500 mm3 in volume.  
Toxicity: Histologic assessment of small bowel crypt density following CRT was used to 
quantify gastrointestinal (GI) toxicity. Small bowel was selected as it is frequently the dose-
limiting structure in pelvic/abdominal CRT.9 Tumor-free C57bl/J6 mice were treated with saline 
or NP injections on days 1 and 3 (using the same treatment schedule as that of the in vivo tumor 
efficacy studies) and 3 daily doses of 5 Gy whole abdominal radiation. Mice were euthanized 48 
hours after the final radiation fraction, and distal ilium were harvested and fixed in 4% neutral 
buffered formalin solution overnight, then stored in 70% ethanol prior to being embedded in 
paraffin and processed at the University of North Carolina tissue core facility. Immunostainings 
of paraffin-embedded samples were performed, and antigen retrieval was accomplished by boiling 
samples in a 10 mM sodium citrate buffer at pH 6.0 for 20 min. Samples were incubated with 
rabbit anti-mouse EpCam antibody (1:100, Abcam). Stainings were visualized with Alexa 488-
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conjugated secondary goat antibodies (molecular probes) and nuclei were counterstained with 
DAPI (molecular probes). 
Effects of nanoparticle size on systemic toxicities of Wtmn and KU60019 were measured 
by analyzing complete blood count (CBC with differential) and hepatotoxicity in tumor-free 8 – 
week old C57bl/6J mice treated with the various sized particle formulations on days 1 and 3 
without radiation. Mice were anesthetized with a ketamine/xylazine solution 48 hours after the 
final inection and blood was collected through cardiac puncture. A 100 µL sample of whole blood 
was stored in EDTA-coated tubes at 5°C prior to analysis at the University of North Carolina 
Animal Clinical Core Facility. For hepatotoxicity, a 400 µL sample of whole blood was transferred 
to a serum separator tube and stored at room temperature for 30 min followed by centrifugation at 
5000 x G for 10 min to separate plasma from the cellular components. Isolated plasma was stored 
at 5°C prior to analysis at the UNC Animal Clinical Core Facility. Pink samples (indicating 
hemolysis) and sample readings which exceeded 3 standard deviations of the mean were presumed 
to be hemolyzed and discarded, as hemolysis can contaminate samples with target enzymes 
coming from somewhere besides the liver (n = 2 for saline treated mice and n = 1 for all other 
groups).  
Biodistribution: Nude mice were inoculated with HT-29 xenografts (1 x 106 cells). Seven 
days after inoculation, the average tumor size was 150 mm3. Tumors were treated with 3 daily 
doses of 5 Gy radiation. After the third fraction of radiation, the mice were injected with saline or 
165 mg/kg Flamma Fluor-labeled nanoparticles by IV tail vein injection. Anesthetic overdose was 
administered, and the animals were decapitated to harvest target organs (heart, liver, spleen, tumor 
xenograft) 1, 3, 6, 12, and 24 h after injection for ex vivo imaging. Fluorescent images were 
obtained using an IVIS Living Image system (Caliper Life Science, Hopkiton, MA) equipped with 
16 
 
an excitation filter of 640 nm and an emission filter of 680 nm in the University of North Carolina 
Small Animal Imaging Facility. Region of interest values were recorded as photon flux in total 
photon count per cm2 per steradian.  
Statistical Analysis 
 In vitro cytotoxicity was assessed using two-way analysis of variance (ANOVA) using 
Prism software (Carlesbad, CA) with particle size and drug concentration as variables. Clonogenic 
cell survival assays were plotted in a linear quadratic regression calculated using CS Cal 
clonogenic survival calculation software pack. Hematologic and hepatotoxicity were assessed 
using one-way ANOVA of particle size Post-hoc analysis were performed with Tukey’s t test when 
significant main effects were identified. In vivo tumor growth was assessed using area under the 
curve analysis with R software.  
Results 
Nanoparticle Size Distribution 
 Nanoparticle KU60019 and Wtmn were engineered with average sizes of 50, 100, and 150 
nm by altering polymeric compositions. The nanoprecipitation method produced monodisperse 
populations of nanoparticles with polydispersity indices (PDIs) of less than 0.1. Table 1 shows the 
polymeric formulations used to generate each size as well as the mean particles sizes and PDIs. 
Figure 2 shows representative TEM images of Wtmn and KU60019 nanoformulations, size 
distribution plots showing virtually no overlap between the largest and smallest sized particles, 
and release rates for all three sizes of both drugs demonstrating almost identical release rates.  
Formulation Mean Diameter PDI 
5000:10000 Da PEG-PLGA 10% Wtmn 48.4 +/- 1.1 nm 0.07 +/- 0.02 
2000:15000 Da PEG-PLGA 38% PLA 10% Wtmn 101.5 +/- 2.1 nm 0.06 +/- 0.02 
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2000:15000 Da PEG-PLGA 56% PLA 5% Wtmn 147.3 +/- 2.4 nm 0.08 +/- 0.04 
5000:10000 Da PEG-PLGA 10% KU600019 44.3 +/- 0.9 nm 0.07 +/- 0.03 
2000:15000 Da PEG-PLGA 38% PLA 10% KU60019 94.6  +/- 1.8 nm 0.08 +/- 0.02 
2000:15000 Da PEG-PLGA 56% PLA 5% KU60019 138 +/- 2.4 nm 0.09 +/- 0.03 
Table 1. Polymeric nanoparticle composition and physical characteristics.  
In Vitro Efficacy 
 Nanoformulations of Wtmn and KU60019 showed comparable levels of cytotoxicity in the 
absence of radiation (figure 2, top panels). The IC90 for both drugs was about 20 µM in HT-29 
and SW480 cells and about 10 µM in LoVo. Particle size did not affect cytotoxicity in vitro.  
Wtmn particles potential sensitized all three cell lines to radiation at doses corresponding 
to roughly the IC90. Cells treated with KU60019 particles showed significantly more potent 
radiosensitization in comparision to Wtmn in vitro, and drug dose was reduced to nearly 1/10th the 
IC90 in order to observe enough colony formation to permit quantification. Again, there was no 
significant effect of particle size for either drug (figure 2, bottom panels).  
In Vivo Efficacy 
Antitumor efficacy of particles as both chemotherapeutics and as radiosensitizers were 
tested by injecting mice with HT-29 or SW480 xenografts and treatments of equivalent doses of 
each of the different sized NPs. All nanoformulations had little to no effect on tumor growth in the 
absence of radiation (figure 3). By comparison, nanoformulations of both drugs demonstrated 
potent radiosensitization to both types of tumors (figure 4). There was a slight trend (P < 0.10) of 
improved sensitization with 100 nm nanoparticles in both xenograft models with both drugs. 
Treatment with the 50 nm particles did not result in greater antitumor efficacy than the larger 
particles in vivo in any cases. 
 
18 
 
 
Figure 1. Top: TEM images of Wortmannin and KU60019 nanoparticles. Middle: Size distribution plots 
demonstrating virtually no overlap between the largest and smallest sized particles. Bottom: All three sizes had similar 
release rates for both drugs.  
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Figure 2. In vitro efficacy of drug-loaded NPs. Top two panels: Toxicity of drug-loaded particles without radiation in 
three rectal cancer cell lines. Bottom two panels: Radiosensitization of rectal cancer cell lines by polymeric Wtmn and 
KU60019 nanoparticles.  
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Figure 3. In vivo efficacy of drug-loaded nanoparticles without radiation. Tumor growth curves of mice bearing HT-
29 (left panels) or SW480 (right panels) xenografts treated with Wtmn (top panels) or KU60019 (bottom panels) 
nanoparticles. Black circles represent saline treated controls. Red open circles represent mice treated with 50 nm NPs. 
Blue triangles represent mice treated with 100 nm NPs. Purple triangles represent animals treated with 150 nm NPs. 
 
In Vivo Toxicity 
 Small bowel crypt density was measured to quantify GI toxicity 48 h after the final fraction 
of whole abdominal radiation (figure 4). Radiation with free drugs produced a substantial decrease 
in crypt density, while nanoformulation largely reduced the synergistic toxicity between drug and 
radiation. There was no significant effect of particle size in the Wtmn nanoparticles, while only 
the 50 nm KU60019 were more toxic than the larger particles.  
 
Figure 5. Radiosensitization demonstrating effect of nanoparticle size in vivo. *Significantly different from indicated 
groups. NS non-significant.  
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 Hematologic and hepatic toxicities of each drug were assessed 48 h after treatment with 
two injections of nanoparticles (days 1 and 3) without radiation (table 2). Hepatotoxicity is a major 
barrier to the use of Wtmn clinically as a chemotherapeutic.1 NP formulation greatly reduced this 
effect, with greater AST and ALT levels in mice with NP Wtmn in comparison to saline, but not 
significantly (P < 0.23). Treatment with NP KU60019 did significantly increase plasma AST 
concentrations compared to saline (P < 0.05), but there was no significant effect of particle size on 
the hepatotoxicity of either drug. A CBC of the mice demonstrated that Wtmn particles do cause 
significant decreases in white blood cells, but this effect was relatively small with no effect due to 
particle size. KU60019 nanoparticles had no effect on any CBC variables. 
Liver Function 
 Wortmannin KU60019 
 AST ALT AST ALT 
Normal Range 30 – 60 U/L 30 – 60 U/L 30 – 60 U/L 30 – 60 U/L 
Saline 57.5 +/- 6.2 36.8 +/- 3.1 57.5 +/- 6.2 36.8 +/- 3.1 
50 nm 76.3 +/- 5.6 41.3 +/- 4.0 77.6 +/- 5.1* 33.6 +/- 2.2 
100 nm 71.3 +/- 4.0 40.1 +/- 2.0 80.0 +/- 5.9* 39.6 +/- 1.3 
150 nm 69.7 +/- 5.6 44.4 +/- 2.7 81.7 +/- 6.2* 37.2 +/- 1.3 
Hematologic Profile 
 Hb (g/dL) Hct (%) RBC (106/µL) Hb (g/dL) Hct (%) RBC (106/µL) 
Normal  10.1 – 16. 1  32.8 – 48 6.5 – 10.1 10.1 – 16.1 32.8 - 48 6.5 – 10.1 
Saline 15.6 +/- 0.2 46.6 +/- 0.7 9.7 +/- 0.1 15.6 +/- 0.2 46.6 +/- 0.7 9.7 +/- 0.1 
50 nm 15.8 +/- 0.4 45.9 +/- 0.8 9.8 +/- 0.2 15.4 +/- 0.2 45.2 +/- 1.0 9.6 +/- 0.2 
100 nm 16.0 +/- 0.3 46.9 +/- 0.7 9.9 +/- 0.2 15.7 +/- 0.3 46.8 +/- 1.1 9.8 +/- 0.2 
150 nm 15.8 +/- 0.4 46.1 +/- 0.5 9.6 +/- 0.2 15.2 +/- 0.2 45.3 +/- 0.8 9.5 +/- 0.2 
 
 WBC 
(103/µL) 
Lymphocytes 
(103/µL) 
Granulocytes 
(103/µL) 
Monocytes 
(103/µL) 
WBC 
(103/µL) 
Lymphocytes 
(103/µL) 
Granulocytes 
(103/µL) 
Monocytes 
(103/µL) 
Normal 2.6 – 10.1 1.3 – 8.4 0.4 – 2.0 0 – 0.3 2.6 – 10.1  1.3 – 8.4 0.4 – 2.0 0 – 0.3 
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Saline 5.5 +/- 0.6 4.5 +/- 0.4 0.6 +/- 0.2 0.5 +/- 0.1  5.5 +/- 0.6 4.5 +/- 0.4 0.6 +/- 0.2 0.5 +/- 0.1 
50 nm 2.8 +/- 0.8* 2.2 +/- 0.9* 0.2 +/- 0.1 0.3 +/- 0.1* 4.3 +/- 0.4 3.7 +/- 0.3 0.4 +/- 0.1 0.3 +/- 0.6 
100 nm 2.9 +/- 0.6* 2.6 +/- 0.6* 0.1 +/- 0.1 0.2 +/- 0.1* 3.8 +/- 0.5 3.3 +/- 0.4 0.2 +/- 0.1 0.3 +/- 0.1 
150 nm 3.0 +/- 0.8* 2.5 +/- 0.7* 0.2 +/- 0.1 0.3 +/- 0.1* 4.1 +/- 0.5 3.6 +/- 0.5 0.2 +/- 0.1 0.3 +/- 0.1 
Table 2. Plasma levels of liver enzymes AST and ALT shown on top table (Wtmn left, KU60019 right). Peripheral 
blood values for specific hematologic values (hemoglobin (Hb), hematocrit (HCT), red blood cells (RBC), white blood 
cells (WBC), lymphocytes, granulocytes, and monocytes. *Significantly different from saline-treated controls. 
 
Biodistribution 
 Effect of particle size on biodistribution was tested by injecting NPs labeled with a flamma 
fluor fluorescent tag and imaging organs (heart, liver, spleen, tumor xenograft) harvested at 1, 3, 
6, 12, and 24 h after drug administration. Figure 6 depicts representative images of organs 
normalized to the unlabeled control background. The 150 nm particles rapidly accumulated in the 
liver and the spleen. The 100 nm particles accumulated more in the liver and spleen than the 50 
nm particles, but less than the 150 nm particles. NPs of all sizes accumulated within tumors at 
similar overall average intensity levels but was most homogenous among the 50 nm particles.  
Discussion 
 Several studies have shown the potential of nanoformulations of radiosensitizing drugs to 
improve the therapeutic index of CRT. However, very little is known about the optimal particle 
characteristics for use in CRT. Here, we compared the efficacy and toxicity of nanoparticles 
ranging from 50 – 150 nm in diameter, a size range consistent with nanoparticles currently in 
clinical development.10 While our data does support previous publications that suggest sub-50 nm 
nanoparticles penetrate tumors more homogenously than larger particles, we were unable to 
demonstrate any therapeutic advantage to using sub-50 nm nanoparticles when combined with 
radiation. Our results suggest that using sub-50 nm NPs may not be optimal for use in CRT. 
 In addition to size, physical characteristics of particles which affect drug release kinetics 
are also important determinants of therapeutic efficacy in CRT. Particles of different sizes but 
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identical release rates were engineered to minimize the effects of variables other than size on 
 
Figure 6. Effect of particle size on in vivo biodistribution. Background-normalized images of various organs harvested 
6 h after in vivo administration of fluorescent-labeled nanoparticles (50 nm left, 100 nm middle, 150 nm right). Far 
right column shows accumulation of particles in the different organs at different times over 24 h. *Significantly more 
than 50 nm. **Significantly more than all other groups.  
 
toxicity and efficacy. A particularly difficult variable to control for is drug sequestration within 
particles of different sizes. Small changes in particle diameter result in relatively large changes in 
particle volume (V = 4/3πr3). Consequently, equal weights of polymer produce substantially fewer 
particles with considerably more drug per particle when formulating larger particles. How drug 
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sequestration within particles affects therapeutic efficacy and toxicity in CRT is unknown. It is 
possible that larger particles could at least partially offset poorer tumor penetration by delivering 
more drug per particle.  
 As chemotherapeutics, NP formulations of Wtmn and KU60019 had similar cytotoxic 
efficacies in vitro and that there was no effect due to particle size. When combined with radiation, 
NP formulations of KU60019 were substantially more toxic than Wtmn particles in vitro. 
Interestingly, this difference in efficacy between Wtmn and KU60019 particles with radiation was 
not observed in vivo. There are multiple significant differences between the two drug formulations 
which could affect their relative efficacy. For example, the two drugs have very different release 
kinetics, and the optimal time interval between radiation and particle administration in vivo is 
likely quite different between slow and fast releasing drugs. The purpose of this study was not to 
compare the relative efficacy of Wtmn and KU60019 nanoformulations, but rather to demonstrate 
that the effect of particle size on CRT was conserved across nanoformulations of different 
radiosensitizing drgus. the optimal administration of individual drugs will need to be considered 
on a case-by-case basis and is beyond the scope of this research. 
 We hypothesized that the smallest particles may have better therapeutic efficacy in vivo, 
since they should be more penetrating. However, in no instance was the 50 nm nanoformulation 
any more efficacious than the larger particles. Indeed, there was greater radiosensitization in the 
100 nm nanoparticles. Differences in tumor penetration with particle size may partially explain 
this observation. Indirectly ionizing radiation (such as photons) is dependent upon sufficient 
oxygen levels in the immediate vicinity of the site of damage.11 Tumor oxygenation is highly 
heterogeneous with areas of relatively high and low oxygenation and DNA repair inhibitors are 
only minimally sensitizing in the absence of oxygen.12 By distributing homogeneously within 
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tumors, the smallest particles are indiscriminately localizing drug in oxygen-rich and hypoxic 
regions. In contrast, larger particles accumulate within the perivascular space, thus concentrating 
drug within the oxygenated tumor regions which are most likely to benefit from 
radiosensitization.13 The 100 nm nanoparticles may be optimal because they provide the best 
balance between tumor penetration and perivascular accumulation. Whether this benefit is 
maintained over more protracted treatment schedules like those utilized in the clinic remains to be 
seen.  
 NP formulations of all sizes were well tolerated with CRT. Although it may be predicted 
that little leaking of 50 nm NPs through unaffected normal tissue vasculature would occur, it is 
possible that vascular damage caused by radiation may preferentially allow more tissue penetration 
of the 50 nm particles than the larger particles.14 Toxicity in the GI tract specifically was studied 
because this area receives the highest doses of radiation during treatment for colorectal cancer.15 
No significant increase in radiation-induced toxicity was identified with the smallest particles. In 
fact, no particles of any size increased rectal toxicity compared to radiation alone. Some 
measurable systemic toxicity was observed in terms of increased plasma liver enzymes and 
decreased blood counts following nanoparticle administration. However, there was no effect due 
to particle size. Further, these effects were relatively small, and no mice demonstrated any obvious 
outward signs of treatment-related toxicity such as lethargy or weight loss.  
 In line with previous studies, we demonstrated that larger nanoparticles more rapidly 
accumulate in the liver and spleen.16 By also measuring therapeutic efficacy and toxicity, two 
important observations were presented. First, increased hepatic and splenic clearance of larger 
particles does not translate into decreased efficacy with CRT. Even though a larger fraction of the 
total particle population is cleared, tumor accumulation still appears to be adequate with larger 
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particles. Second, increasing hepatic accumulations of particles encapsulating hepatotoxic drugs 
does not increase the hepatotoxicity of larger particles. Exactly how the liver clears drug from 
particles without incurring excess toxicity is currently unclear. The results of our study suggest 
that differences in biodistribution patterns with particle size do not necessarily translate into 
predictable changes in toxicity or efficacy when combined with radiation.  
 A few other limitations to this study should be considered. First, we engineered particles 
over a fairly large size range. It is possible that particle sizes between the tested ranges offer 
therapeutic advantages compared to the sizes actually tested in these experiments. Second, while 
we used a fractionated treatment regimen to mimic clinical delivery of CRT, this only consisted of 
3 fractions of radiation and 2 injections of drug. Clinical CRT treatments tend occur over a longer 
and more separated period of time (20 – 30 fractions over 4 – 6 weeks),17 and it is possible that 
changes in tumor or normal tissue vasculature in this setting may produce toxicity and/or efficacy 
profiles which more clearly favor a particular NP size. Finally, xenograft models of tumors were 
used, which have different physiological properties than native tumors, particularly with respect 
to the microenvironment surrounding the tumor. This likely limits our ability to extrapolate our 
results to spontaneously-occurring human tumors.  
Conclusions 
 This study has demonstrated that nanoparticles encapsulating radiosensitizing drugs in 
clinically relevant size ranges (50 – 150 nm) are potent radiosensitizers and well-tolerated in vivo. 
Our results are the first to suggest that engineering sub-50 nm particles may not be optimal for use 
in chemoradiotherapy. While particle size has very clear effects on biodistribution and tumor 
penetration, its effects on antitumor efficacy when combined with radiation are more subtle and 
do not demonstrate any advantage to using small sized NPs. Indeed, when significant differences 
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in efficacy were observed, they favored the 100 nm nanoparticles over the other sizes. Whether 
this difference is observed in clinical practice or other model systems remains to be seen. 
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Abbreviations 
 
ACN    Acetonitrile 
CRT    Chemoradiotherapy 
DMEM   Dulbecco’s Modified Eagle Medium 
DPBS    Dulbecco’s phosphate-buffered saline 
Gy    Gray (SI unit) 
HPLC    High-pressure liquid chromatography  
mPEG-PLGA   Methoxy-poly(ethylene glycol)-block-poly(lactic-co-glycolic acid)  
NP    Nanoparticle 
PBS    Phosphate-buffered saline 
PDI    Polydispersity index 
PLA    Poly(D,L-lactic acid)      
TEM    Transmission electron microscopy 
Wtmn    Wortmannin 
 
